Clinical Trial Update: Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravitreal topotecan for repair of rhegmatogenous retinal detachment with proliferative vitreoretinopathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Vitreoretinopathy
• Rhegmatogenous Retinal Detachment

Drugs mentioned

• Topotecan (topotecan)

Snippet

Sponsor: Unity Health Toronto | Conditions: Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment | Phase 2 | Status: RECRUITING